PHOENIX, AZ
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION, founded in 2004, is a mid-sized nonprofit in the Medical Research sector that reported $11.0M in total revenue in fiscal year 2023. Revenue fell 28% from the prior year — a significant decline worth monitoring.
Fundraising and development functions for The Translational Genomics Research Institute ("TGen"), Western Regional Medical Center, Inc. ("COH Phoenix") and their respective affiliates, which are 501(c)(3) tax-exempt organizations.
SCIENCE, BY NATURE, IS AN ITERATIVE PROCESS: A QUESTION AND ANSWER CYCLE OF REFINEMENT AND FURTHER EXPERIMENTATION IN SEARCH OF MEDICAL ADVANCES, WHETHER A NEW DIAGNOSTIC TEST OR TREATMENT. IN THIS...
SCIENCE, BY NATURE, IS AN ITERATIVE PROCESS: A QUESTION AND ANSWER CYCLE OF REFINEMENT AND FURTHER EXPERIMENTATION IN SEARCH OF MEDICAL ADVANCES, WHETHER A NEW DIAGNOSTIC TEST OR TREATMENT. IN THIS REGARD, TGEN HAS HELPED BRIDGE THE GAP BETWEEN LABORATORY DISCOVERIES AND PRACTICAL APPLICATIONS IN PATIENT CARE. OUR APPROACH HAS LED TO SIGNIFICANT STRIDES IN UNDERSTANDING DISEASES AT THE MOLECULAR LEVEL, PAVING THE WAY FOR MORE PRECISE DIAGNOSTIC TOOLS AND GROUNDBREAKING TREATMENTS. TODAY, OUR CAPACITY TO UNDERSTAND AND LEVERAGE INFORMATION FROM THE HUMAN GENOME HAS NEVER BEEN GREATER. TGEN'S ABILITY TO BRING EMERGING NEW METHODS FOR INTERROGATING A PATIENT'S GENOME INTO THE CLINICAL CARE OF PATIENTS, THE REVOLUTION IN FASTER AND LOWER-COST WAYS OF CANCER DETECTION AND THE PATHS THAT REACH THE URBAN, THE RURAL AND MORE DIVERSE POPULATIONS, HAS NEVER BEEN GREATER. THE SEQUENCE COST PER-PATIENT OVER THE PAST DECADE HAS DROPPED DRAMATICALLY. THIS MEANS TGEN CAN SEQUENCE MORE PATIENTS, OR SEQUENCE A PATIENT AGAIN, TO UNDERSTAND HOW THEIR DISEASE IS PROGRESSING. AS PART OF A NATIONAL HEALTH SYSTEM, THIS HELPS DRIVE RESEARCH DISCOVERY, NEW METHODS FOR EARLY DETECTION, AND MORE CLINICAL TRIALS. SEQUENCING ACCURACY HAS ALSO IMPROVED DRAMATICALLY. THIS INCREASED ACCURACY MEANS TGEN CAN DETECT CANCER EARLIER - PERHAPS IN ITS INFANCY - WHICH LEADS TO IMPROVED SCREENING, POST-TREATMENT MONITORING AND BIOPSIES WITH A LOW PERCENTAGE OF TUMOR PRESENT. THIS ALSO ALLOWS US TO EXPAND GENOMIC TESTING INTO MORE CANCER TYPES.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $11,047,177 | $15,400,764 | -0.3% |
| Expenses | $11,619,212 | $16,987,277 | -0.3% |
| Net Income | $-572,035 | $-1,586,513 | -0.6% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| BENNETT DORRANCE | BOARD MEMBER/CHAIRMAN | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| ERIN MASSEY | CHIEF DEVELOPMENT OFFICER | 40.0 |
Officer
Director
|
$0 | $25,660 | $386,023 |
| KEN KENDRICK | BOARD MEMBER/SECRETARY | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| RICHARD J LEHMANN | BOARD MEMBER/TREASURER | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| ALAN POWELL | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| BILL POPE | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| CATHERINE IVY | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| DAVID LANE | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| FRED SHAULIS | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| GLENN D STEELE MD PHD | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| HOWARD YOUNG | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| J DANFORTH QUAYLE | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| JEFFREY M TRENT PHD | BOARD MEMBER | 1.0 |
Director
|
$0 | $343,288 | $1,876,254 |
| KEVIN TULIPANA DO MS | BOARD MEMBER | 1.0 |
Director
|
$0 | $39,884 | $606,014 |
| LYNDA CARTER ALTMAN | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| MICHEAL KAPLAN | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| MIKE INGRAM | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| PHIL FRANCIS | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| STEVE HILTON | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| STEVE STAGNER | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| TERESA BURLESON | BOARD MEMBER/TGEN COO | 1.0 |
Director
|
$0 | $31,378 | $749,378 |
| TROY RICHARDS | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| WILLIAM J POST | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| MANUEL ESTRADA | CFO/ASSISTANT TREASURER | 0.0 |
Officer
|
$0 | $36,511 | $475,653 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $11,047,177 | $11,619,212 | $22,786,653 | $-572,035 |
| 2023 | $15,400,764 | $16,987,277 | $22,611,724 | $-1,586,513 |
| 2022 | $11,571,587 | $13,079,297 | $24,398,471 | $-1,507,710 |
| 2021 | $3,772,453 | $14,242,203 | $24,235,369 | $-10,469,750 |
| 2020 | $23,062,861 | $12,328,866 | $36,934,555 | $10,733,995 |
| 2019 | $9,102,928 | $9,749,790 | $24,732,906 | $-646,862 |
| 2018 | $5,440,855 | $7,578,274 | $24,428,539 | $-2,137,419 |
Compare THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION with other nonprofits in Arizona and across the country.